

Immuno-Oncology and Lung Cancer: Emerging Data and Recent Developments

Monday, 5 December 2016 | 12:45–14:15
Messe Wien Exhibition & Congress Center
Hall D, Plenary Room
Vienna, Austria



Bristol-Myers Squibb



Immuno-Oncology

Immuno-Oncology and Lung Cancer: Emerging Data and Recent Developments

Monday, 5 December 2016 | 12:45–14:15
Messe Wien Exhibition & Congress Center
Hall D, Plenary Room
Vienna, Austria

Programme:



Developments in the Use of I-O Monotherapy in Lung Cancers

Enriqueta Felip, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain



Meeting Chair

Rationale for Studying I-O Combo Therapies to Address Unmet Needs in Lung Cancer

Matthew Hellmann, MD
Memorial Sloan Kettering Cancer Center
New York, United States



Clinical Lessons Learned for the Use of I-O Therapies

Jürgen Wolf, MD, PhD
University Hospital of Cologne
Cologne, Germany

Full panel discussion to follow presentations

This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.



Bristol-Myers Squibb



Immuno-Oncology